M42 And Toshiba Collaborate To Launch Middle East's First Heavy-Ion Therapy Facility In Abu Dhabi

M42, a global leader in health innovation, has announced plans to establish the Middle East's first heavy-ion therapy facility in Abu Dhabi. This initiative, in partnership with Cleveland Clinic Abu Dhabi, aims to provide advanced cancer treatment options to patients across the region. The announcement was made during Abu Dhabi Global Health Week 2025, an event organised by the Department of Health – Abu Dhabi to promote future health advancements.

The new facility will be constructed at Cleveland Clinic Abu Dhabi's campus starting in 2026. It will be located next to the Fatima bint Mubarak Center, which offers a comprehensive approach to cancer care. The heavy-ion therapy system will feature two treatment rooms: one with a rotating gantry and another with a fixed horizontal beam. This technology promises precise targeting of cancerous tumours.

M42 and Toshiba Energy Systems & Solutions Corporation (Toshiba ESS) have formed a strategic partnership for this project. By combining M42’s healthcare expertise with Toshiba ESS’s technological advancements, they aim to position Abu Dhabi as a hub for innovative cancer treatment. The agreement was signed by Hasan Jasem Al Nowais of M42 and Tsutomu Takeuchi of Toshiba ESS.

Heavy-ion therapy is an advanced form of radiation therapy that offers greater precision and efficacy in destroying cancer cells. This technology fills a critical gap in the region's healthcare offerings, providing hope for patients who previously had limited options. With no similar facility within a five-hour flight radius of the UAE, this centre will ensure access to world-class care.

Hasan Jasem Al Nowais emphasised the importance of this collaboration for the UAE and its residents. He stated, "M42’s partnership with Toshiba ESS is a significant step that reinforces our commitment to reshaping the future of global health through cutting-edge innovations and technologies." This sentiment highlights the project's potential impact on regional healthcare.

Tsutomu Takeuchi from Toshiba ESS expressed enthusiasm about the partnership's potential benefits. He noted that heavy-ion therapy represents a major advancement in radiation treatment, offering faster and less frequent sessions for patients. This collaboration aims to transform cancer care in the Middle East.

Commitment to Oncology Innovation

Dr. Georges-Pascal Haber of Cleveland Clinic Abu Dhabi highlighted their dedication to advancing cancer care through innovative treatments. "At Cleveland Clinic Abu Dhabi, we are committed to our mission to bring the world’s most advanced cancer treatment modalities to our patients," he stated. The introduction of heavy-ion therapy aligns with their goal of enhancing oncology outcomes.

This development underscores Cleveland Clinic Abu Dhabi's role as a leader in personalised oncology care. By integrating this technology into their programme, they aim to improve patient outcomes and offer renewed hope for those facing complex cancer diagnoses. The facility sets a new standard for cancer treatment in the region.

The upcoming private ceremony in Japan will celebrate this significant milestone in regional healthcare evolution. As construction begins on this state-of-the-art facility, it marks an important step forward in providing cutting-edge cancer treatments to patients across the Middle East.

With inputs from WAM